[go: up one dir, main page]

WO2011097166A9 - Polythérapie destinée à traiter le cancer comprenant un inhibiteur de l'igf-1r et un inhibiteur de la hdac - Google Patents

Polythérapie destinée à traiter le cancer comprenant un inhibiteur de l'igf-1r et un inhibiteur de la hdac Download PDF

Info

Publication number
WO2011097166A9
WO2011097166A9 PCT/US2011/023154 US2011023154W WO2011097166A9 WO 2011097166 A9 WO2011097166 A9 WO 2011097166A9 US 2011023154 W US2011023154 W US 2011023154W WO 2011097166 A9 WO2011097166 A9 WO 2011097166A9
Authority
WO
WIPO (PCT)
Prior art keywords
inhibitor
igf
combination therapy
treating cancer
hdac
Prior art date
Legal status (The legal status is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the status listed.)
Ceased
Application number
PCT/US2011/023154
Other languages
English (en)
Other versions
WO2011097166A2 (fr
Inventor
Ho-Young Lee
Current Assignee (The listed assignees may be inaccurate. Google has not performed a legal analysis and makes no representation or warranty as to the accuracy of the list.)
University of Texas System
University of Texas at Austin
Original Assignee
University of Texas System
University of Texas at Austin
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Application filed by University of Texas System, University of Texas at Austin filed Critical University of Texas System
Priority to EP11740231A priority Critical patent/EP2531185A2/fr
Publication of WO2011097166A2 publication Critical patent/WO2011097166A2/fr
Anticipated expiration legal-status Critical
Publication of WO2011097166A9 publication Critical patent/WO2011097166A9/fr
Ceased legal-status Critical Current

Links

Classifications

    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K45/00—Medicinal preparations containing active ingredients not provided for in groups A61K31/00 - A61K41/00
    • A61K45/06—Mixtures of active ingredients without chemical characterisation, e.g. antiphlogistics and cardiaca
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A61K31/16—Amides, e.g. hydroxamic acids
    • A61K31/165—Amides, e.g. hydroxamic acids having aromatic rings, e.g. colchicine, atenolol, progabide
    • A61K31/167—Amides, e.g. hydroxamic acids having aromatic rings, e.g. colchicine, atenolol, progabide having the nitrogen of a carboxamide group directly attached to the aromatic ring, e.g. lidocaine, paracetamol
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K39/00—Medicinal preparations containing antigens or antibodies
    • A61K39/395—Antibodies; Immunoglobulins; Immune serum, e.g. antilymphocytic serum
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K16/00—Immunoglobulins [IGs], e.g. monoclonal or polyclonal antibodies
    • C07K16/18—Immunoglobulins [IGs], e.g. monoclonal or polyclonal antibodies against material from animals or humans
    • C07K16/28—Immunoglobulins [IGs], e.g. monoclonal or polyclonal antibodies against material from animals or humans against receptors, cell surface antigens or cell surface determinants
    • C07K16/2863—Immunoglobulins [IGs], e.g. monoclonal or polyclonal antibodies against material from animals or humans against receptors, cell surface antigens or cell surface determinants against receptors for growth factors, growth regulators
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K2317/00—Immunoglobulins specific features
    • C07K2317/50—Immunoglobulins specific features characterized by immunoglobulin fragments
    • C07K2317/56—Immunoglobulins specific features characterized by immunoglobulin fragments variable (Fv) region, i.e. VH and/or VL
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K2317/00—Immunoglobulins specific features
    • C07K2317/50—Immunoglobulins specific features characterized by immunoglobulin fragments
    • C07K2317/56—Immunoglobulins specific features characterized by immunoglobulin fragments variable (Fv) region, i.e. VH and/or VL
    • C07K2317/565—Complementarity determining region [CDR]

Landscapes

  • Health & Medical Sciences (AREA)
  • Chemical & Material Sciences (AREA)
  • Medicinal Chemistry (AREA)
  • Life Sciences & Earth Sciences (AREA)
  • General Health & Medical Sciences (AREA)
  • Pharmacology & Pharmacy (AREA)
  • Epidemiology (AREA)
  • Animal Behavior & Ethology (AREA)
  • Public Health (AREA)
  • Veterinary Medicine (AREA)
  • Immunology (AREA)
  • Organic Chemistry (AREA)
  • Biochemistry (AREA)
  • Biophysics (AREA)
  • Genetics & Genomics (AREA)
  • Molecular Biology (AREA)
  • Proteomics, Peptides & Aminoacids (AREA)
  • Pain & Pain Management (AREA)
  • Engineering & Computer Science (AREA)
  • Bioinformatics & Cheminformatics (AREA)
  • Microbiology (AREA)
  • Mycology (AREA)
  • Pharmaceuticals Containing Other Organic And Inorganic Compounds (AREA)
  • Medicines That Contain Protein Lipid Enzymes And Other Medicines (AREA)
  • Medicines Containing Antibodies Or Antigens For Use As Internal Diagnostic Agents (AREA)
PCT/US2011/023154 2010-02-02 2011-01-31 Polythérapie destinée à traiter le cancer comprenant un inhibiteur de l'igf-1r et un inhibiteur de la hdac Ceased WO2011097166A2 (fr)

Priority Applications (1)

Application Number Priority Date Filing Date Title
EP11740231A EP2531185A2 (fr) 2010-02-02 2011-01-31 Polythérapie destinée à traiter le cancer comprenant un inhibiteur de l'igf-1r et un inhibiteur de la hdac

Applications Claiming Priority (2)

Application Number Priority Date Filing Date Title
US30064310P 2010-02-02 2010-02-02
US61/300,643 2010-02-02

Publications (2)

Publication Number Publication Date
WO2011097166A2 WO2011097166A2 (fr) 2011-08-11
WO2011097166A9 true WO2011097166A9 (fr) 2013-07-25

Family

ID=44356045

Family Applications (1)

Application Number Title Priority Date Filing Date
PCT/US2011/023154 Ceased WO2011097166A2 (fr) 2010-02-02 2011-01-31 Polythérapie destinée à traiter le cancer comprenant un inhibiteur de l'igf-1r et un inhibiteur de la hdac

Country Status (2)

Country Link
EP (1) EP2531185A2 (fr)
WO (1) WO2011097166A2 (fr)

Families Citing this family (8)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
CN104276979B (zh) * 2013-07-10 2018-09-07 江苏豪森药业集团有限公司 阿戈美拉汀中间体的制备方法
CN104693058A (zh) * 2013-12-04 2015-06-10 山东新时代药业有限公司 一种辛酰苯胺酸甲酯制备方法
WO2015153820A1 (fr) * 2014-04-02 2015-10-08 Felder Mitchell S Blocage de ctl-4 combiné à la chimiothérapie métronomique pour le traitement du cancer
CN104649925A (zh) * 2015-02-13 2015-05-27 山东新时代药业有限公司 一种伏立诺他中间体的制备方法
CN105777582B (zh) * 2016-05-05 2017-08-04 青岛市市立医院 一种制备抗癌药物伏立诺他的方法
CN106008267B (zh) * 2016-06-27 2018-04-06 马腾 一种抗癌药物伏立诺他的制备方法
US11554123B2 (en) 2017-03-01 2023-01-17 Saint Joseph's University Compositions and methods for reactivating latent HIV-1 infections
TW202436324A (zh) * 2022-11-25 2024-09-16 大陸商成都微芯新域生物技術有限公司 一種連接子、含連接子的抗體藥物偶聯物及其製備方法和應用

Also Published As

Publication number Publication date
EP2531185A2 (fr) 2012-12-12
WO2011097166A2 (fr) 2011-08-11

Similar Documents

Publication Publication Date Title
IL276362A (en) Cancer treatment methods
EP2549963A4 (fr) Systèmes et procédés de traitement de la prostate
ZA201300567B (en) Methods and compositions for liver cancer therapy
EP2600783A4 (fr) Systèmes et procédés de traitement ultrasonore
EP2542584B8 (fr) Méthodes de traitement du cancer du pancréas
EP2564200B8 (fr) Biomarqueurs de cancer et leurs procédés d'utilisation
WO2012015937A9 (fr) Thérapie ciblée sur parp1
SG10201500124VA (en) Methods and Compositions for Treating Cancer
WO2011097166A9 (fr) Polythérapie destinée à traiter le cancer comprenant un inhibiteur de l'igf-1r et un inhibiteur de la hdac
ZA201304226B (en) Methods of treating cancer
EP2544767A4 (fr) Applicateur de thérapie ultrasonore
EP2640390A4 (fr) Procédés de traitement du cancer
EP2590712A4 (fr) Système et procédé pour un traitement hyperthermique de tumeur
EP2593111A4 (fr) Nouveaux composés pour traiter le cancer et d'autres maladies
WO2011130486A9 (fr) Traitements combinatoires et formulations pour le cancer
PL2619331T3 (pl) Sposoby leczenia nowotworu obejmujące ukierunkowanie na nqo1
WO2012003421A9 (fr) Compositions et procédés combinatoires de traitement du cancer
EP2585115A4 (fr) Traitement anticancéreux
EP2625743A4 (fr) Appareil à antenne et procédés
EP2537031A4 (fr) Compositions et méthodes pour le traitement du cancer
WO2012037553A9 (fr) Utilisation d'inhibiteurs de pkc iota dans le traitement du cancer du sein
WO2011130429A9 (fr) Procédés et matériaux pour le traitement du cancer pulmonaire
HK1180935A (en) Systems and methods for prostate treatment
HK1189267A (zh) 治疗癌症的方法
HK1189268A (en) Methods of treating cancer

Legal Events

Date Code Title Description
121 Ep: the epo has been informed by wipo that ep was designated in this application

Ref document number: 11740231

Country of ref document: EP

Kind code of ref document: A1

WWE Wipo information: entry into national phase

Ref document number: 2011740231

Country of ref document: EP

NENP Non-entry into the national phase in:

Ref country code: DE